SOLVE FSHD Invests US $1 Million in miRecule to Accelerate Development of Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy Sep 30, 2022 | NewRead the press release here: SOLVE-FSHD Invests US 1 Million in miRecule to Accelerate Development of Best-in-Class Antibody-RNA-Conjugate to Treat Facioscapulohumeral Muscular...
miRecule Inc. closes $5.7M to create breakthrough RNA therapies for cancer & muscular dystrophy May 27, 2021 | NewRead the full story here: Global News...
